ORYX’s oncolytic parvovirus H1 successfully completes Phase I/IIa trial to treat glioblastoma multiforme
12 June 2015 | By Victoria White
ORYX's Phase I/IIa trial assessing oncolytic parvovirus H1 as a treatment for patients with glioblastoma multiforme has been successfully completed...